Scientific Advisory Board

The Scientific Advisory Board is comprised of individuals who are leaders in gene control, chemistry, biology and oncology.

Richard A. Young, Ph.D.*,  Whitehead Institute, Massachusetts Institute of Technology

James "Jay" E. Bradner, M.D.*,  Harvard Medical School, Dana Farber Cancer Institute, Broad Institute

Nathanael Gray, Ph.D.*,  Harvard Medical School, Dana Farber Cancer Institute

Bradley Bernstein, M.D., Ph.D.,  Massachusetts General Hospital, Harvard Stem Cell Institute, Harvard Medical School, Howard Hughes Medical Institute, Broad Institute

Scott Biller, Ph.D.,  Agios

Gerard Evan, Ph.D., FRS, FMedSci,  University of Cambridge, European Molecular Biology, UK Academy of Medical Sciences, Royal Society

William Kaelin, M.D.,  Dana Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School and Harvard Cancer Center, Howard Hughes Medical Institute

Stefan Knapp, Ph.D.,  Target Discovery Institute, Structuralb Genomics Consortium, University of Oxford

Mark Murcko, Ph.D.,  Disruptive Biomedical, LLC; Professor of Practice, Northeastern University; Lecturer, Massachusetts Institute of Technology

Aviv Regev, Ph.D.,  Massachusetts Institute of Technology, Broad Institute, Howard Hughes Medical Institute, Klarman Cell Observatory

Phillip Sharp, Ph.D.,  Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology

Roger Tung, Ph.D.,  Concert Pharmaceuticals

Chris Vakoc, M.D., Ph.D.,  Cold Spring Harbor Lab

Bob Weinberg, Ph.D.,  Whitehead Institute, Massachusetts Institute of Technology, MIT Ludwig Center for Molecular Oncology


*Scientific founders of Syros Pharmaceuticals